drugset / Trial / NCT02497222

Pilot Study of RNS60 in Allergen-induced Bronchoconstriction

NCT02497222

Phase 2 Withdrawn Revalesio Corporation
Non-randomizedCrossoverSingle-blindTreatment

Summary

This study evaluates the use of RNS60 in the treatment of asthma examining regional improvements in inflammation using PET imaging. All subjects will be treated with both RNS60 and placebo in a crossover design.

Timeline

Start
Primary completion
2016-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject RNS60 Other / unclassified 4 ml Inhaled

Indications